Onegene Biotechnology is a biological drug development company, which is specialized in multi-target therapeutics, treating complex and chronic
diseases. We have established protein-binding platform technology (named as UniStac) optimizing for multi-target therapeutic development and
suggested new directions for findings and development of metabolic diseases, cancer immunotherapy, ant-inflammatory therapeutics, etc.
Furthermore, our goal is to provide a better life for people with chronic diseases with our multi-target innovative new drug pipelines.
Liver Fibrosis Microenvironment
dedicated platform and NASH & beyond
Multiple mechanisms are involved in the onset and progression of NASH and fibrosis. Proinflammatory cytokines and free fatty acid interact with a
hepatic microenvironment composed of Kupffer cells, T cells, antigen-presenting cells, and hepatic stellate cells. Such interactions lead to pro-
inflammatory and pro-fibrotic microenvironments for NASH, fibrosis and cirrhosis progression. This complex nature of the NASH pathogenesis raised
a question on whether single targeted treatment would be effective enough.
Onegene's approach is simple. We develop a microenvironment-targeting drug that can modulate many targets synergistically. In this light, Onegene
developed a dedicated platform for protein drugs harboring more than three ligands.
Our goal is to open new therapeutic opportunities for people who suffered from NASH, organ fibrosis and cancers.